WALTHAM, MA—Kelly William John, the Chief Financial Officer and Treasurer of Vicarious Surgical Inc. (NYSE:RBOT), recently sold shares of the company's Class A common stock. According to a recent SEC filing, Mr. Kelly sold 218 shares on December 3, resulting in a total transaction value of $2,923. The transaction comes amid RBOT's impressive market performance, with the stock delivering a 77.79% return over the past year and currently trading at $17.19.
The shares were sold at a weighted average price of $13.4094 per share, with individual transaction prices ranging from $12.60 to $14.66. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units granted earlier in the year on June 2, 2023. According to InvestingPro data, RBOT maintains a strong balance sheet with more cash than debt, and analysis suggests the stock may be slightly undervalued at current levels.
Following this transaction, Mr. Kelly holds 12,260 shares of Vicarious Surgical's Class A common stock. For deeper insights into RBOT's valuation and financial health metrics, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Vicarious Surgical Inc. shared its third-quarter results, revealing a narrowed net loss of $17 million, a decrease from the previous year's $20.4 million. The company's operating expenses also saw a 17% year-over-year decline, totaling $17.8 million. Piper Sandler adjusted its outlook on Vicarious Surgical, reducing the price target to $10.50 from $12.00 while maintaining a neutral rating, following the earnings report.
Vicarious Surgical also confirmed its commitment to the previously stated full-year 2024 cash burn guidance of approximately $50 million. The company is nearing the completion of its single-port robotic surgery platform, with the first patient expected to be treated within a year, starting with ventral hernia repairs in clinical trials outside the U.S.
In addition, Vicarious Surgical is in the process of selecting specific sites for an overseas clinical trial for ventral hernia, as part of its strategy to advance its clinical programs and prepare for commercialization. Piper Sandler acknowledged the long-term potential of Vicarious Surgical's differentiated technology, expressing enthusiasm for the company's innovative approach while awaiting further progress and clearer visibility towards commercial success. These are the recent developments shaping Vicarious Surgical's journey.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.